There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Dehydroepiandrosterone-sulphate replacement improves the human plasma fatty acid profile in plasma of obese women
DHEA-S treatment is used as an anti-aging and anti-obesity hormone therapy in adults ; however , it mechanisms of action are not clearly eluci date d. The objective of the present work was to analyze the effect of a replacement therapy , which included a daily single oral dose of DHEA-S for three months , on the composition of human plasma fatty acids ( FAs ) in obese women . In the first study , a r and omized , double-blind , placebo-controlled trial was conducted involving 61 postmenopausal women , who were assigned to receive 100mg/day of DHEA-S ( n = 41 ) or placebo ( n = 20 ) orally for 3 months . In a second study , the effect of DHEA-S treatment on postmenopausal obese women ( n = 41 ) was compared to that in premenopausal obese women ( n = 20 ) . Blood sample s were collected at the beginning and at the end of the treatment . Plasma FAs were analyzed by gas chromatography . DHEA-S treatment produced significant changes in plasma FAs of both post- and premenopausal women with a reduction of total saturated FAs ( SFA ) as well as an increase in n-6 polyunsaturated FA ( PUFA ) . Particularly , in premenopausal women the DHEA-S treatment also increased the plasma n-3 PUFA percentage . Regarding estimation of desaturase activity , our data showed that Δ6-desaturase was significantly decreased in postmenopausal women after DHEA-S treatment , whereas Δ5-desaturase was increased in the premenopausal group . In conclusion , DHEA-S treatment in obese women  modifies plasma FA composition towards a potentially better metabolic profile , mainly by decreasing SFA and increasing n-6 PUFA in both postmenopausal and premenopausal women
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .